Cantor Fitzgerald Predicts CVRx FY2025 Earnings

CVRx, Inc. (NASDAQ:CVRX) – Analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of CVRx in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn expects that the company will post earnings of ($1.58) per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $14.00 price objective on the stock. The consensus estimate for CVRx’s current full-year earnings is ($2.61) per share.

CVRX has been the topic of several other reports. Lake Street Capital raised their target price on CVRx from $12.00 to $15.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. Canaccord Genuity Group increased their price target on shares of CVRx from $17.00 to $22.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. Piper Sandler reiterated an “overweight” rating and set a $16.00 price target (up previously from $13.00) on shares of CVRx in a research note on Wednesday, October 30th. William Blair upgraded CVRx from a “market perform” rating to an “outperform” rating in a research note on Tuesday, January 14th. Finally, Craig Hallum lifted their target price on CVRx from $20.00 to $22.00 and gave the company a “buy” rating in a research report on Friday, January 17th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $17.00.

CVRx Stock Performance

CVRX stock opened at $18.40 on Wednesday. The company has a debt-to-equity ratio of 0.76, a current ratio of 11.32 and a quick ratio of 10.23. CVRx has a 1 year low of $6.40 and a 1 year high of $29.23. The company has a market cap of $446.38 million, a P/E ratio of -6.81 and a beta of 1.26. The stock’s fifty day moving average price is $14.21 and its 200-day moving average price is $11.20.

CVRx (NASDAQ:CVRX) last issued its quarterly earnings data on Tuesday, October 29th. The company reported ($0.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.12). CVRx had a negative net margin of 123.75% and a negative return on equity of 89.06%. The company had revenue of $13.37 million for the quarter, compared to the consensus estimate of $13.28 million. During the same quarter last year, the company earned ($0.43) EPS.

Hedge Funds Weigh In On CVRx

Several large investors have recently made changes to their positions in the business. Barclays PLC raised its stake in CVRx by 312.5% during the 3rd quarter. Barclays PLC now owns 19,067 shares of the company’s stock valued at $169,000 after purchasing an additional 14,445 shares during the period. Geode Capital Management LLC raised its position in shares of CVRx by 2.2% during the third quarter. Geode Capital Management LLC now owns 295,124 shares of the company’s stock valued at $2,600,000 after buying an additional 6,443 shares during the last quarter. XTX Topco Ltd purchased a new position in shares of CVRx in the third quarter worth $150,000. Jane Street Group LLC boosted its position in shares of CVRx by 36.1% during the third quarter. Jane Street Group LLC now owns 19,038 shares of the company’s stock worth $168,000 after acquiring an additional 5,053 shares during the last quarter. Finally, State Street Corp grew its stake in CVRx by 11.4% during the third quarter. State Street Corp now owns 264,733 shares of the company’s stock valued at $2,332,000 after acquiring an additional 27,071 shares in the last quarter. 75.27% of the stock is currently owned by hedge funds and other institutional investors.

About CVRx

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.